HOME > BUSINESS > Biocon’s European approval for cholesterol drug opens $1.2 billion market

Biocon’s European approval for cholesterol drug opens $1.2 billion market

crestor

Biocon Ltd said it has received European approvals for generic versions of AstraZeneca’s cholesterol drug Crestor, opening up a billion dollar market.

The approval has been obtained for Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, indicated for hyperlipidemia or mixed dyslipidemia.

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: “This approval paves the way for Biocon to launch Rosuvastatin Calcium tablets in several European countries. We plan to collaborate with regional partners in the near term to provide access to this affordable generic and thus help patients and governments to bring down their healthcare spends.”

“This first generic formulations approval in the regulated markets marks an important milestone in Biocon’s small molecules strategy of forward integration from APIs to finished dosages.

“The approval for Rosuvastatin Calcium, through decentralized procedure will open the doors for Biocon to over 15 European countries and will enable the company to address US$ 1.2 billion opportunity, starting FY17,” the company said.

Biocon was the first generic company to receive a Certificate of Suitability for Rosuvastatin Calcium API from the European Directorate for the Ouality of Medicines. CEP certification indicates that an API is suitable for use in medicinal products in the
EU.

Arun Chandavarkar, CEO and Joint Managing Director, Biocon said: “The European approval for Biocon’s generic version of Rosuvastatin Calcium underscores Biocon’s unique strengths in the chronic therapies space and our compliance with global standards that enable us to achieve the highest quality standards for all our products. It augurs well for this nascent business, which will be one of our growth drivers in the coming years.”

Biocon aims to rev up its generic formulations business with a target of 20-25 filings over the next few years. Its new potent oral solid dosage formulations facility coming up in Bengaluru will enable this business expansion, the company said.

The company is also working on dossiers to introduce these formulations in emerging markets where regulatory clearances are primarily based on approvals given by regulators in the US / EU.

Biocon has a portfolio of drugs spanning complex molecules ranging from cardiovascular and anti-obesity agents to immunosuppressants and narrow spectrum antibiotics.

It had filed an initial set of Marketing Authorization Applications (MAAS) in the EU and Abbreviated New Drug Applications (ANDAs) in the US in ΡΥ15.

Follow ULTRA.news
Zee Entertainment slashes channel prices ahead of TRAI regulation Zee's new tariff card for HD channelsZee Entertainment, one of the four big broadcasting groups of India, has become the first player to bring its channel prices in line with an upcoming regulation issued by the Telecom Regulatory Authority of India.Zee's new tariff card...
Net Neutrality: Vodafone wants right to manipulate Internet videos Telcos want to be able to reduce video qualityVodafone India said it would like to be given the power to manage the size of videos watched by users on its mobile network and lower it automatically "for overall quality welfare".Participating in the discussions related to ...
Govt of India starts crack down on low-quality medicine makers The government of India has started conducting inspections at drug manufacturing units across the country to prevent the production of low-quality drugs and medicines in India.Typically, inspections are conducted by state authorities, while central agencies largely confin...
Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been termi...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta ta...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharm...
Mylan and Biocon submits breast cancer drug application to USFDA Mylan N.V. and Biocon Ltd. said they submitted Mylan’s biologics license application for a proposed biosimilar Trastuzumab, to the U.S. Food and Drug Administration.Biosimilar trastuzumab is a proposed biosimilar to branded Trastuzumab, which is indicated to treat certain HER...
Reliance Jio interconnect dispute with Airtel, Idea to end this month The dispute over providing interconnection facility is set to end in the next two weeks, with Bharti Airtel, Idea Cellular and Vodafone giving in to the demands of new operator Reliance Jio and the regulator.The decision to comply comes in the wake of a recommendation for a f...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being de...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement sett...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in t...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supp...
Lupin licenses taste-masking technology from Monosol for paediatric tablets Pharma Major Lupin Ltd. said its US subsidiary, Lupin Pharmaceutical Inc., has agreed to license technology from Monosol Rx to develop multiple paediatric-focused products.Lupin would develop the pediatric products utilizing MonoSol Rx’s proprietary PharmFilm drug delivery ...
Cadila to launch immunosuppressant drug in India Cadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body's immune system in India.The drug named Grafalon...
Almebic Pharmaceuticals receives inspection report from USFDA Alembic Pharmaceuticals Ltd., said it received an Establishment Inspection Report from the United States Food and Drug Administration for the inspection carried out at their formulation facility at Panelav, Gujarat.The FDA has the authority to inspect any establishment in whi...
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and ...
FDA observations ‘primarily procedural’ – USFDA issued four observations about Cipla's manufacturing facilities in Goa after conducting an audit, the company said. Cipla has three facilities in Goa."The observations were primarily procedural in nature and the company has already responded to these observations," said...
Lupin receives FDA approval for generic Namenda XR dementia capsules Pharma Major Lupin Ltd said it received final approval from United States Food and Drug Administration for selling Memantine Hydrochloride extended-release capsules, a generic version of Allergan’s Namenda XR capsules.Namenda XR extended-release capsules are approved by the...
Kilitch Drugs to set up plant in Ethiopia Kilitch Drugs (India) Ltd said its unit Kilitch Estro Biotech Plc acquired land for the installation of a pharma plant in Ethiopia.4317.5 sq. mtrs of land was allotted at Oromia special zone by the Bureau of Rural Land and Environmental Protection, Federal Democratic Republic...
Suven Life Sciences gets two product patents in India and Japan Drug manufacturer Suven Life Sciences Ltd said it got two product patents in India and Japan for to a new compound for the treatment of disorders associated with Neurodegenerative diseases.The patents are valid through 2026-2032.The granted claims include a class of selec...
Marksans Pharma gets USFDA approval for sale of anti-allergy drug Marksans Pharma Limited, an Indian pharmaceutical company, said it has received approval from the USFDA for the sale sale of its Loratadine Liquid Filled Capsules 10 mg in the US market.Loratadine is an antihistamine that reduces the effects of natural chemical histamine in t...
Lincoln Pharma develops oral spray version of Ondansetron anti-nausea drug Lincoln Pharmaceuticals Ltd said it developed and launched an oral spray version of Ondansetron anti-nausea drug.Ondansetron is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy), radiation therapy and also in the prevention and treatment for n...
Aurobindo Pharma to launch HIV drug in Africa this year, gets tentative FDA nod Aurobindo Pharma Limited, a pharmaceutical manufacturing company based in Hyderabad, said it received a tentative approval for HIV drug Dolutegravir from US Food & Drug Administration.It is the first FDA approval of a generic version of Dolutegravir. Through a tie up w...